Thus, an alternative therapeutic strategy would be to utilize ephrin-mimetics (agonistic agents) targeting its ligand-binding domain to ameliorate MN cell death induced by overexpression of EphA4 in patients with ALS with rapid disease progression. Here, EPHA4 is linked to amyotrophic lateral sclerosis.